[Remote] Senior Manager, Clinical Supply Chain at Abata Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Skills

Key technologies and capabilities for this role

Clinical Supply Chain ManagementDemand ForecastingInventory ManagementGlobal LogisticsImport/ExportCMC ManufacturingQuality AssuranceClinical OperationsCDMO Management3PL ManagementCRO ManagementProduct CommercializationDistribution

Questions & Answers

Common questions about this position

What experience is essential for the Senior Manager, Clinical Supply Chain role?

Prior experience overseeing a global clinical supply chain (EU, LATAM, APAC, etc.) is essential, with a highly preferred background in clinical demand planning, logistics, and product commercialization and distribution.

What are the key responsibilities in clinical supply planning for this position?

Responsibilities include developing and executing comprehensive clinical supply plans, including demand forecasting, inventory management, and allocation strategies to support ongoing and upcoming clinical trials.

Is this a remote position or does it require office presence?

This information is not specified in the job description.

What is the salary or compensation for this role?

This information is not specified in the job description.

What makes a strong candidate for this Senior Manager role?

A strong candidate will have prior experience overseeing a global clinical supply chain across regions like EU, LATAM, and APAC, plus preferred expertise in clinical demand planning, logistics, and product commercialization, along with the ability to build partnerships with CMC, QA, Clinical Ops, and external providers.

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free